Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

John Porter, MD, Ali T Taher, MD, Yesim Aydinok, MD, Maria D Cappellini, Antonis Kattamis, MD, Ali El-Ali, MD, Nicolas Martin, MS, Dudley Pennell, MD, FRCP

Blood (2013) 122 (21): 1016.

https://doi.org/10.1182/blood.V122.21.1016.1016

Published: 2013

Journal Articles

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Dudley Pennell, MD, John B. Porter, MD, Maria Domenica Cappellini, MD, Lee Lee Chan, MD, Amal El-Beshlawy, MD, Yesim Aydinok, MD, Hishamshah Ibrahim, MD, Chi-Kong Li, MD, Vip Viprakasit, MD, DPhil, Mohsen Saleh Elalfy, MD, Antonis Kattamis, MD, Gillian Smith, MSc, Dany Habr, MD, Gabor Domokos, PhD, Bernard Roubert, PhD, Ali Taher, MD

Blood (2010) 116 (21): 4276.

https://doi.org/10.1182/blood.V116.21.4276.4276

Published: 2010

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, John B Porter, Maria Domenica Cappellini, Chi-Kong Li, Yesim Aydinok, Chan Lee Lee, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Abdel Hmissi, Ali Taher

Blood (2008) 112 (11): 3873.

https://doi.org/10.1182/blood.V112.11.3873.3873

Published: 2008

Journal Articles

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Dudley Pennell, Pranee Sutcharitchan, Amal El-Beshlawy, Yesim Aydinok, Ali Taher, Gillian Smith, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, John B Porter

Blood (2008) 112 (11): 3874.

https://doi.org/10.1182/blood.V112.11.3874.3874

Published: 2008

Journal Articles

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

Maciej Garbowski, Perla Eleftheriou, Dudley Pennell, Mark Tanner, John B Porter

Blood (2008) 112 (11): 116.

https://doi.org/10.1182/blood.V112.11.116.116

Published: 2008

NARROW

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

Email alerts

ASH Publications

American Society of Hematology

Impact Of Liver Iron Overload On Myocardial T2* Response In Transfusion-Dependent Thalassemia Major Patients Treated With Deferasirox For Up To 3 Years

Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years

Efficacy and Safety of Deferasirox (Exjade ® ) in Reducing Cardiac Iron in Patients with β-Thalassemia Major: Results from the Cardiac Substudy of the EPIC Trial

Efficacy and Safety of Deferasirox (Exjade ® ) in Preventing Cardiac Iron Overload in β-Thalassemia Patients with Normal Baseline Cardiac Iron: Results from the Cardiac Substudy of the EPIC Trial

Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only